Celularity Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Robin L Smith. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Robin L Smith has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CELU / Celularity Inc. Director 236,066
US:SRNE / Sorrento Therapeutics, Inc. Director 0
US:SREV / ServiceSource International Inc Director 167,975
US:SEEL / Seelos Therapeutics, Inc. Director 16,000
US:RMTI / Rockwell Medical, Inc. Director 22,461
US:MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) Director 100,000
US:LUNG / Pulmonx Corporation Director 7,320
US:SGNL / Signal Genetics, Inc. Director 0
US:NBS / Executive Chair of the Board, Director 347,285
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Robin L Smith. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CELU / Celularity Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CELU / Celularity Inc. Insider Trades
Insider Sales CELU / Celularity Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CELU / Celularity Inc. Insider Trades
Insider Purchases LSTA / Lisata Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2012-09-18 (NBS Smith Robin L 36,000 0.6900 2,880 8.6250 24,840 730 5.2 -9,864 -39.71

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Sales LSTA / Lisata Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Purchases LUNG / Pulmonx Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LUNG / Pulmonx Corporation Insider Trades
Insider Sales LUNG / Pulmonx Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LUNG / Pulmonx Corporation Insider Trades
Insider Purchases MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2016-12-13 MYAN Smith Robin L 5,000 6.0000 5,000 6.0000 30,000 1 9.3500 16,750 55.83

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) Insider Trades
Insider Sales MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) Insider Trades
Insider Purchases RMTI / Rockwell Medical, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RMTI / Rockwell Medical, Inc. Insider Trades
Insider Sales RMTI / Rockwell Medical, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RMTI / Rockwell Medical, Inc. Insider Trades
Insider Purchases SEELQ / Seelos Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SEELQ / Seelos Therapeutics, Inc. Insider Trades
Insider Sales SEELQ / Seelos Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SEELQ / Seelos Therapeutics, Inc. Insider Trades
Insider Purchases SRNE / Sorrento Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-03-05 SRNE Smith Robin L 40,000 2.2724 40,000 2.2724 90,896 158 18.82 661,904 728.20

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SRNE / Sorrento Therapeutics, Inc. Insider Trades
Insider Sales SRNE / Sorrento Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SRNE / Sorrento Therapeutics, Inc. Insider Trades
Insider Purchases VRDN / Viridian Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRDN / Viridian Therapeutics, Inc. Insider Trades
Insider Sales VRDN / Viridian Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRDN / Viridian Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Robin L Smith as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-06-16 2023-06-14 4 CELU Celularity Inc
Class A Common Stock
A - Award 199,921 236,066 553.11
2022-07-15 2022-07-13 4 CELU Celularity Inc
Class A Common Stock
A - Award 36,145 36,145
2021-09-13 2021-09-09 4 CELU Celularity Inc
Stock Option (Right to Buy)
A - Award 56,053 56,053
2021-09-03 2021-09-03 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
M - Exercise -100,000 0 -100.00
2021-09-03 2021-09-03 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
M - Exercise -75,000 0 -100.00
2021-09-03 2021-09-03 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
M - Exercise 100,000 235,000 74.07 4.89 489,000 1,149,150
2021-09-03 2021-09-03 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
M - Exercise 75,000 135,000 125.00 3.95 296,250 533,250
2021-08-30 2021-08-30 4 SRNE Sorrento Therapeutics, Inc.
Stock option (right to buy)
A - Award 250,000 250,000
2021-07-20 2021-07-16 4 CELU Celularity Inc
Deferred Compensation Award (Right to Buy)
A - Award 269,007 269,007
2021-07-20 2021-07-16 4 CELU Celularity Inc
Stock Option (Right to Buy)
A - Award 384,297 384,297
2020-06-15 2020-06-15 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 100,000 100,000
2020-05-21 2020-05-20 4 SREV SERVICESOURCE INTERNATIONAL, INC.
Common Stock
P - Purchase 50,000 167,975 42.38 1.70 85,000 285,558
2020-05-14 2020-05-14 4 SREV SERVICESOURCE INTERNATIONAL, INC.
Common Stock
A - Award 100,000 117,975 556.33
2020-03-06 2020-03-05 4 SREV SERVICESOURCE INTERNATIONAL, INC.
Common Stock
A - Award 17,975 17,975
2020-03-05 2020-03-05 4 SRNE Sorrento Therapeutics, Inc.
Common Stock
P - Purchase 40,000 60,000 200.00 2.27 90,896 136,344
2020-01-07 2020-01-06 4 SEEL SEELOS THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 16,000 16,000
2019-12-18 2019-12-16 4 SRNE Sorrento Therapeutics, Inc.
Stock Options
A - Award 75,000 75,000
2019-12-18 3 SRNE Sorrento Therapeutics, Inc.
Common Stock
40,000
2019-12-18 3 SRNE Sorrento Therapeutics, Inc.
Common Stock
40,000
2019-12-18 3 SRNE Sorrento Therapeutics, Inc.
Common Stock
40,000
2019-06-10 2019-06-06 4 RMTI ROCKWELL MEDICAL, INC.
Stock Option (Right to Buy)
A - Award 22,461 22,461
2019-06-10 2019-06-06 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
A - Award 21,566 31,366 220.06
2019-05-10 2019-05-08 4 MYND MYnd Analytics, Inc.
EMPLOYEE STOCK OPTION (right to purchase
A - Award 100,000 100,000
2019-05-10 2019-05-08 4 MYND MYnd Analytics, Inc.
Common Stock
A - Award 50,000 211,539 30.95 1.19 59,500 251,731
2019-03-21 2019-03-20 4 SEEL SEELOS THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 16,000 16,000
2019-03-21 2019-03-20 4 SEEL SEELOS THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 24,000 24,000
2018-10-10 2018-10-08 4 MYND MYnd Analytics, Inc.
EMPLOYEE STOCK OPTION (right to purchase)
A - Award 48,000 48,000
2018-09-25 2018-09-24 4 MYND MYnd Analytics, Inc.
Common Stock Purchase Warrant
A - Award 13,513 13,513
2018-09-25 2018-09-24 4 MYND MYnd Analytics, Inc.
Common Stock
A - Award 13,513 161,539 9.13 1.85 24,999 298,847
2018-05-14 2018-05-08 4 None PROLUNG INC
Employee Stock Option (right to buy)
A - Award 7,320 7,320
2018-04-24 2018-04-16 4/A MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 50,000 50,000
2018-04-24 2018-04-04 4/A MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 75,000 75,000
2018-04-24 2018-04-04 4/A MYND MYnd Analytics, Inc.
Common Stock
A - Award 25,000 148,026 20.32
2018-04-20 2018-04-16 4 MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 150,000 150,000
2018-04-20 2018-04-04 4 MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 75,000 75,000
2018-04-20 2018-04-04 4 MYND MYnd Analytics, Inc.
Common Stock
A - Award 25,000 148,026 20.32
2018-03-21 2018-03-19 4 RMTI ROCKWELL MEDICAL, INC.
Stock Option (Right to Buy)
A - Award 38,985 38,985
2017-11-20 2017-11-13 4 MYND MYnd Analytics, Inc.
Common Stock
A - Award 7,500 123,026 6.49
2017-08-30 2017-08-24 4 [None] PROLUNG INC
Employee Stock Option (right to buy)
A - Award 70,000 70,000
2017-08-30 2017-08-24 4 [None] PROLUNG INC
Employee Stock Option (right to buy)
A - Award 30,000 30,000
2017-08-30 2017-08-24 4 [None] PROLUNG INC
Employee Stock Option (right to buy)
A - Award 20,000 20,000
2017-08-23 2017-08-21 4 MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 50,000 50,000
2017-08-23 2017-08-21 4 MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 75,000 75,000
2017-08-10 2017-08-08 4 MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 8,000 40,000 25.00
2017-07-18 2017-07-14 4 MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 8,000 32,000 33.33
2017-07-18 2017-07-14 4 MYND MYnd Analytics, Inc.
Common Stock
A - Award 25,000 115,526 27.62
2017-07-18 2016-11-07 4 MYND MYnd Analytics, Inc.
Employee Stock Option (right to buy)
A - Award 8,000 24,000 50.00
2017-06-14 2017-02-10 4 [NONE] PROLUNG INC
Common Stock
A - Award 30,000 30,000
2017-06-14 2017-02-01 4/A [NONE] PROLUNG INC
Common Stock
A - Award 30,000 30,000
2017-03-23 2017-03-21 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
A - Award 9,800 9,800
2017-02-07 2017-02-03 4 SGNL SIGNAL GENETICS, INC.
Stock Option (Right to Buy)
M - Exercise -1,200 0 -100.00
2017-02-07 2017-02-03 4 SGNL SIGNAL GENETICS, INC.
Common Stock
M - Exercise 1,200 1,900 171.43 7.65 9,180 14,535
2016-12-14 2016-12-13 4 MYAN MYnd Analytics, Inc.
Common Stock
P - Purchase 5,000 90,526 5.85 6.00 30,000 543,156
2016-12-02 2016-11-30 4 MYAN MYnd Analytics, Inc.
Common Stock
A - Award 16,000 85,526 23.01 6.25 100,000 534,538
2016-11-02 2016-11-01 4 MYAN MYnd Analytics, Inc.
Employee Stock Option (right to buy) and tax-offset right
A - Award 16,000 16,000
2016-11-02 2016-11-01 4 MYAN MYnd Analytics, Inc.
Common Stock
A - Award 40,000 69,526 135.47
2016-09-23 2016-09-21 4 CNSO MYnd Analytics, Inc.
Common Stock Warrant
D - Sale to Issuer 0
2016-09-23 2016-09-21 4 CNSO MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017
M - Exercise
2016-09-23 2016-09-21 4 CNSO MYnd Analytics, Inc.
Common Stock
M - Exercise 20,776 29,526 237.44 5.00 103,880 147,630
2016-09-23 2016-09-21 4 RMTI ROCKWELL MEDICAL, INC.
Stock Option (right to buy)
A - Award 25,000 25,000
2016-06-27 3 RMTI ROCKWELL MEDICAL, INC.
Common Stock
0
2016-06-20 2016-06-15 4 SGNL SIGNAL GENETICS, INC.
Stock Option (Right to Buy)
A - Award 18,000 18,000
2016-04-25 2016-04-21 4 CNSO MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017
A - Award 2,000,000
2016-04-25 2016-04-21 4 CNSO MYnd Analytics, Inc.
Common Stock Warrant
A - Award 800,000 2,000,000 66.67
2016-04-07 2016-04-05 4 CNSO MYnd Analytics, Inc.
Common Stock
A - Award 1,000,000 1,750,000 133.33
2015-12-28 2015-12-23 4 CNSO MYnd Analytics, Inc.
Common Stock Warrant
A - Award 1,200,000 1,200,000
2015-09-16 2015-09-14 4 CNSO CNS RESPONSE, INC.
5% Secured Convertible Note due March 2016
A - Award
2015-08-24 2015-08-20 4 CNSO CNS RESPONSE, INC.
Option to Purchase
A - Award 250,000 250,000
2015-08-24 2015-08-20 4 CNSO CNS RESPONSE, INC.
Common Stock
A - Award 750,000 750,000
2015-08-10 2015-08-06 4 SGNL SIGNAL GENETICS, INC.
Stock Option (Right to Buy)
A - Award 18,000 18,000
2015-08-10 2015-08-06 4 SGNL SIGNAL GENETICS, INC.
Restricted Stock Units
M - Exercise -4,125 0 -100.00
2015-08-10 2015-08-06 4 SGNL SIGNAL GENETICS, INC.
Common Stock
A - Award 5,000 10,500 90.91
2015-08-10 2015-08-06 4 SGNL SIGNAL GENETICS, INC.
Common Stock
M - Exercise 4,125 5,500 300.00
2015-07-21 2015-07-17 4 SGNL SIGNAL GENETICS, INC.
Restricted Stock Units
M - Exercise -1,375 4,125 -25.00
2015-07-21 2015-07-17 4 SGNL SIGNAL GENETICS, INC.
Common Stock
M - Exercise 1,375 1,375
2015-06-04 2015-06-02 4 NBS NeoStem, Inc.
Common Stock, par value $0.001 per share
A - Award 40,000 347,285 13.02
2015-01-21 2015-01-16 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
D - Sale to Issuer -50,000 250,000 -16.67
2015-01-21 2015-01-16 4 NBS NeoStem, Inc.
Common Stock, par value $0.001 per share
F - Taxes -20,117 309,293 -6.11 3.48 -70,007 1,076,340
2015-01-21 2015-01-16 4 NBS NeoStem, Inc.
Common Stock, par value $0.001 per share
A - Award 39,276 329,410 13.54
2015-01-05 2015-01-02 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 300,000 300,000
2015-01-02 2015-01-02 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 150,000 150,000
2015-01-02 2014-12-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 3,476 290,134 1.21 3.20 11,139 929,734
2014-08-01 2014-08-01 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 75,000 75,000
2014-07-21 2014-07-17 4 SGNL SIGNAL GENETICS, INC.
Restricted Stock Units
A - Award 5,500 5,500
2014-07-21 2014-07-17 4 SGNL SIGNAL GENETICS, INC.
Stock Option (right to buy)
A - Award 6,000 6,000
2014-07-01 2014-06-30 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 2,010 286,658 0.71 5.54 11,139 1,588,659
2014-01-03 2014-01-02 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 131,000 131,000
2014-01-03 2014-01-02 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 94,000 284,648 49.31
2014-01-03 2013-12-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 2,093 190,648 1.11 4.84 10,141 923,690
2013-03-07 2013-03-06 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 100,000 1,849,553 5.72 0.53 53,000 980,263
2013-01-04 2013-01-02 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 500,000 500,000
2012-09-18 2012-09-18 4 (NBS NeoStem, Inc.
Common stock, $0.001 par value per share
P - Purchase 36,000 1,749,533 2.10 0.69 24,840 1,207,178
2012-08-17 2012-08-16 4 NBS NeoStem, Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -54,000 0 -100.00
2012-08-17 2012-08-16 4 NBS NeoStem, Inc.
Common stock, $0.001 par value
A - Award 54,000 1,713,533 3.25
2012-07-06 2012-07-05 4 NBS NeoStem, Inc.
Stock Option (Right to Buy)
A - Award 700,000 700,000
2012-07-06 2012-07-05 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 150,000 1,659,533 9.94 0.52 78,000 862,957
2012-04-30 2012-04-30 4 NBS NeoStem, Inc.
Common stock, $0.001 par value
A - Award 24,872 1,509,553 1.68 0.36 8,954 543,439
2012-04-30 2012-04-26 4 NBS NeoStem, Inc.
Stock Option (Right to Buy)
A - Award 402,627 402,627
2012-04-16 2012-04-13 4 NBS NeoStem, Inc.
Common stock, $0.001 par value
A - Award 26,313 1,484,681 1.80 0.33 8,683 489,945
2012-04-03 2012-03-30 4 NBS NeoStem, Inc.
Common stock, $0.001 par value
A - Award 21,653 1,458,368 1.51 0.38 8,228 554,180
2012-03-15 2012-03-15 4 NBS NeoStem, Inc.
Common stock, $0.001 par value
A - Award 14,187 1,436,715 1.00 0.58 8,228 833,295
2012-03-01 2012-02-29 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 14,436 1,422,528 1.03 0.57 8,229 810,841
2012-02-16 2012-02-15 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 12,281 1,408,092 0.88 0.67 8,228 943,422
2012-02-01 2012-01-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 13,061 1,395,811 0.94 0.63 8,228 879,361
2012-01-06 2012-01-04 4 NBS NeoStem, Inc.
Stock Options (Right to Buy)
A - Award 790,000 790,000
2006-06-06 3 PHSM PHASE III MEDICAL INC/DE
Common Stock, $.001 par value
500,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)